A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis

Trial Profile

A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs PTI 428 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Proteostasis Therapeutics
  • Most Recent Events

    • 11 Dec 2017 Results presented in a Proteostasis Therapeutics media release.
    • 14 Nov 2017 According to a Proteostasis Therapeutics media release, the company has completed enrolment and expects preliminary data from part B of this trial in the fourth quarter of 2017. The company has commenced dosing in and expects preliminary data from the 14 days study (part C) in the first quarter of 2018.
    • 19 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top